{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.2","upperLimit":"6.9","value":"5.3"},{"groupId":"OG001","lowerLimit":"5.7","upperLimit":"10.8","value":"8.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"Progression-free survival is defined as time from the date of the first dose of study intervention until progression per RECIST 1.1, as assessed by ICR, or death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Final Analysis with DCO on 06May2024","id":"OG000","title":"TNBC Cohort"},{"description":"Final Analysis with DCO on 27Nov2024","id":"OG001","title":"NSCLC Cohort"}],"paramType":"MEDIAN","populationDescription":"FAS: Enrolled participants who have received at least one dose of treatment. Participants who were enrolled but did not subsequently receive study intervention are not included in the analysis.","reportingStatus":"POSTED","timeFrame":"TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.","title":"Progression-Free Survival (PFS) , Assessed by ICR","type":"SECONDARY","unitOfMeasure":"Month"}